Hypereosinophilic Syndrome, Erythroderma as Clinical Debut. Case Report and Literature Review
Main Article Content
Abstract
Eosinophilia is a common finding in clinical practice, but when elevated values of eosinophils are found, it constitutes a diagnostic challenge. Hypereosinophilic syndrome is a group of rare disorders defined by persistent blood hypereosinophilia >1.5 × 109/l and associated to organ damage that result in a wide variety of clinical manifestations: fatigue with nonspecific skin lesions, to endomyocardial fibrosis, neurological compromise and life-threatening evolution.
The prognosis of the disease is variable and depends on the variant and the availability of specific treatment. 1- 2
We present the clinical case of a patient with a history of B symptoms and the presence of persistent erythroderma. The patient underwent several complementary studies, including skin biopsy without presenting a definitive diagnosis. Laboratory with persistence of hypereosinophilia that guided us towards the diagnosis of Idiopathic Hypereosinophilic Syndrome.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Grzegorz Helbig; Amy D. Klion; (2021). Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Reviews, (), –. doi:10.1016/j.blre.2021.100809
II. Liliana María Tamayo-Quijano, Lina María Aguirre-Hernández. (2018-06-09). Recurrent erythroderma leading to the diagnosis of hypereosinophilic syndrome. Allergy Mexico, 65, supplement 1.
III. Leru, PM Eosinophilic disorders: evaluation of the current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy 9, 36 (2019).https://doi.org/10.1186/s13601-019-0277-4
IV. Gao, Su-jun MD, PhDa; Wei, Wei MD, PhDb; Chen, Jiang-tao MD a ; Tan, Ye-hui MD, PhD; Yu, Cheng-bao MDd ; Litzow, Mark Robert MDc ; Liu, Qiu-ju MD, PhD a,c,* Hypereosinophilic Syndrome Presenting With Multiorgan Infiltration and Deep Vein Thrombosis, Medicine: August 2016 - Volume 95 - Number 35 - p e4658 doi: 10.1097/MD.0000000000004658
V. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related conditions. J Allergy Clin Immunol 2012;130:607–12.
VI. Klion AD. How I treat hypereosinophilic syndromes. Blood 2015;126:1069–77.
VII. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124: 1319–25.
VIII. Legrand F, Renneville A, MacIntyre E, Mastrilli S, Ackermann F, Cayuela JM, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. New insights based on a survey of 44 cases. Medicine. 2013;92:e1–9.
IX. Lefevre G, Copin MC, Staumont-Salle D, Avenel-Audran M, Aubert H, Taieb H, et al. The lymphoid variant of hypereosinophilic syndrome. Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine. 2014;93:255–66.
X. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124: 1319–25.
XI. Kovacs N, Benjamin K, Holland-Thomas N, Moshkovich O, Nelsen LM, Ortega H, et al. Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported tool. J Allergy Clin Immunol Pract 2020;May 15. https://doi. org/10.1016/j.jaip.2020.04.069. S2213-2198(20)30472-4. Online ahead of print.
XII. Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, et al. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Int J Hematol. 2012; 96:320–26.